{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:16:44Z","timestamp":1790129804328,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01NS110703"],"award-info":[{"award-number":["1R01NS110703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1U19CA264338"],"award-info":[{"award-number":["1U19CA264338"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM) remains a formidable challenge in neuro-oncology, with immune checkpoint blockade (ICB) only showing efficacy in some patients, while the mechanisms governing therapeutic responsiveness are poorly defined. Although MAPK\/ERK signaling correlates with survival following ICB, its causal role and mechanisms underlying tumor immunogenicity remain unclear. Here, we perform in vivo kinome-wide CRISPR\/Cas9 screens in murine gliomas where we identify RAF-MEK-ERK axis as the strongest modulators of glioma susceptibility to anti-programmed cell death protein 1 (anti-PD-1) therapy and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell recognition. Experimentally-induced ERK phosphorylation (p-ERK) enhances survival after anti-PD-1 and anti-CTLA-4 therapy, leading to durable antitumor immunity upon rechallenge. Additionally, glioma cell p-ERK promotes increased interferon responses and T cell infiltration. Notably, BRAF\/MEK inhibition disrupts interferon programs and tumor-microglia interactions in\n                    <jats:italic>BRAF<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>V600E<\/jats:italic>\n                    <\/jats:sup>\n                    ex vivo in human GBM\/brain slice cultures. Our findings elucidate that tumor-intrinsic MAPK\/ERK promotes immunotherapy response, interferon responses, T cell tumor infiltration, and GBM cell-microglia interactions.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-74124-7","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:29:15Z","timestamp":1782386955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glioma-intrinsic MAPK\/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses"],"prefix":"10.1038","volume":"17","author":[{"given":"Kwang-Soo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-2971","authenticated-orcid":false,"given":"Junyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-6993","authenticated-orcid":false,"given":"V\u00edctor A.","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1688-9663","authenticated-orcid":false,"given":"Crismita","family":"Dmello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Grabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahaya A.","family":"Yabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Habashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-5504","authenticated-orcid":false,"given":"Rishi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9760-2013","authenticated-orcid":false,"given":"Jian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Balyasnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8124-4399","authenticated-orcid":false,"given":"Dhan","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7001-0226","authenticated-orcid":false,"given":"Peter","family":"Canoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-4837","authenticated-orcid":false,"given":"Peter A.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-9255","authenticated-orcid":false,"given":"Raul","family":"Rabadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-7647","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-8589","authenticated-orcid":false,"given":"Pouya","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-2124","authenticated-orcid":false,"given":"Catalina","family":"Lee-Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-3033","authenticated-orcid":false,"given":"Dieter Henrik","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-1945","authenticated-orcid":false,"given":"Adam M.","family":"Sonabend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"74124_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849 (2019).","journal-title":"Cell"},{"key":"74124_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42\u201356 (2017).","journal-title":"Cancer Cell"},{"key":"74124_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/ijms23031353","volume":"23","author":"AB Behrooz","year":"2022","unstructured":"Behrooz, A. B. et al. Wnt and PI3K\/Akt\/mTOR survival pathways as therapeutic targets in glioblastoma. Int. J. Mol. Sci. 23, 1353 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"74124_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/ijms22020587","volume":"22","author":"A Oprita","year":"2021","unstructured":"Oprita, A. et al. Updated insights on EGFR signaling pathways in glioma. Int. J. Mol. Sci. 22, 587 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"74124_CR5","doi-asserted-by":"crossref","unstructured":"Pearson, J. R. D. & Regad, T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct. Target. Ther. 2, e17040 (2017).","DOI":"10.1038\/sigtrans.2017.40"},{"key":"74124_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00694-8","volume":"19","author":"YX Zhou","year":"2021","unstructured":"Zhou, Y. X. et al. Immuno-oncology: are TAM receptors in glioblastoma friends or foes? Cell Commun. Signal 19, 11 (2021).","journal-title":"Cell Commun. Signal"},{"key":"74124_CR7","doi-asserted-by":"publisher","unstructured":"Arrieta, V. A. et al. The eclectic nature of glioma-infiltrating macrophages and microglia. Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms222413382 (2021).","DOI":"10.3390\/ijms222413382"},{"key":"74124_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/14737175.2018.1510321","volume":"18","author":"MC Morisse","year":"2018","unstructured":"Morisse, M. C., Jouannet, S., Dominguez-Villar, M., Sanson, M. & Idbaih, A. Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies. Expert Rev. Neurother. 18, 729\u2013737 (2018).","journal-title":"Expert Rev. Neurother."},{"key":"74124_CR9","doi-asserted-by":"publisher","unstructured":"Arrieta, V. A. et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J. Clin. Investig. 133, https:\/\/doi.org\/10.1172\/JCI163447 (2023).","DOI":"10.1172\/JCI163447"},{"key":"74124_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fonc.2015.00055","volume":"5","author":"NR Parker","year":"2015","unstructured":"Parker, N. R., Khong, P., Parkinson, J. F., Howell, V. M. & Wheeler, H. R. Molecular heterogeneity in glioblastoma: potential clinical implications. Front. Oncol. 5, 55 (2015).","journal-title":"Front. Oncol."},{"key":"74124_CR11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","volume":"2","author":"VA Arrieta","year":"2021","unstructured":"Arrieta, V. A. et al. ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat. Cancer 2, 1372\u20131386 (2021).","journal-title":"Nat. Cancer"},{"key":"74124_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"74124_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74124_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"74124_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477 (2019).","journal-title":"Nat. Med."},{"key":"74124_CR16","volume":"4","author":"A Omuro","year":"2022","unstructured":"Omuro, A. et al. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neurooncol. Adv. 4, vdac025 (2022).","journal-title":"Neurooncol. Adv."},{"key":"74124_CR17","first-page":"674","volume":"20","author":"A Omuro","year":"2018","unstructured":"Omuro, A. et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. NeuroOncology 20, 674\u2013686 (2018).","journal-title":"NeuroOncology"},{"key":"74124_CR18","doi-asserted-by":"publisher","unstructured":"Arrieta, V. A. et al. ERK1\/2 phosphorylation predicts survival in recurrent glioblastoma following intracerebral and adjuvant PD-1\/CTLA-4 immunotherapy: a REMARK-guided analysis. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1889 (2024).","DOI":"10.1158\/1078-0432.CCR-23-1889"},{"key":"74124_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36878-2","volume":"14","author":"C Dmello","year":"2023","unstructured":"Dmello, C. et al. Checkpoint kinase 1\/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat. Commun. 14, 1566 (2023).","journal-title":"Nat. Commun."},{"key":"74124_CR20","doi-asserted-by":"crossref","unstructured":"Kim, K.-S. et al. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: a novel combinatorial immunotherapy regimen for gliomas. NeuroOncology 26, 2044\u20132060 (2024).","DOI":"10.1093\/neuonc\/noae135"},{"key":"74124_CR21","doi-asserted-by":"publisher","unstructured":"Chen, C. H. et al. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of human disease. NeuroOncology https:\/\/doi.org\/10.1093\/neuonc\/noad025 (2023).","DOI":"10.1093\/neuonc\/noad025"},{"key":"74124_CR22","first-page":"A490","volume":"10","author":"C Delepine","year":"2022","unstructured":"Delepine, C. et al. Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors. J. Immunother. Cancer 10, A490\u2013A490 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"74124_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","volume":"33","author":"JD Waight","year":"2018","unstructured":"Waight, J. D. et al. Selective FcgammaR Co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell 33, 1033\u20131047 (2018).","journal-title":"Cancer Cell"},{"key":"74124_CR24","doi-asserted-by":"publisher","unstructured":"Chand, D. et al. Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0190 (2024).","DOI":"10.1158\/2159-8290.CD-24-0190"},{"key":"74124_CR25","volume":"3","author":"A Qin","year":"2021","unstructured":"Qin, A., Musket, A., Musich, P. R., Schweitzer, J. B. & Xie, Q. Receptor tyrosine kinases as druggable targets in glioblastoma: do signaling pathways matter? Neurooncol. Adv. 3, vdab133 (2021).","journal-title":"Neurooncol. Adv."},{"key":"74124_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31842-y","volume":"13","author":"F Peglion","year":"2022","unstructured":"Peglion, F. et al. PTEN inhibits AMPK to control collective migration. Nat. Commun. 13, 4528 (2022).","journal-title":"Nat. Commun."},{"key":"74124_CR27","doi-asserted-by":"publisher","first-page":"20477","DOI":"10.1073\/pnas.1006646107","volume":"107","author":"EJ Moon","year":"2010","unstructured":"Moon, E. J. et al. NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc. Natl. Acad. Sci. USA 107, 20477\u201320482 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74124_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43201-6","volume":"14","author":"JK Benotmane","year":"2023","unstructured":"Benotmane, J. K. et al. High-sensitive spatially resolved T cell receptor sequencing with SPTCR-seq. Nat. Commun. 14, 7432 (2023).","journal-title":"Nat. Commun."},{"key":"74124_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat. Commun. 13, 925 (2022).","journal-title":"Nat. Commun."},{"key":"74124_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","volume":"19","author":"R Barbosa","year":"2021","unstructured":"Barbosa, R., Acevedo, L. A. & Marmorstein, R. The MEK\/ERK network as a therapeutic target in human cancer. Mol. Cancer Res. 19, 361\u2013374 (2021).","journal-title":"Mol. Cancer Res."},{"key":"74124_CR31","doi-asserted-by":"publisher","unstructured":"Kiyatkin, A., van Alderwerelt van Rosenburgh, I. K., Klein, D. E. & Lemmon, M. A. Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics. Sci Signal 13, https:\/\/doi.org\/10.1126\/scisignal.aaz5267 (2020).","DOI":"10.1126\/scisignal.aaz5267"},{"key":"74124_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"74124_CR33","doi-asserted-by":"publisher","unstructured":"Ruiz-Moreno, C. et al. Harmonized single-cell landscape, intercellular crosstalk and tumor architecture of glioblastoma. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2022.08.27.505439 (2022).","DOI":"10.1101\/2022.08.27.505439"},{"key":"74124_CR34","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/neuonc\/noad101","volume":"25","author":"U Kuliesiute","year":"2023","unstructured":"Kuliesiute, U. et al. Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma. Neuro Oncol. 25, 1963\u20131975 (2023).","journal-title":"Neuro Oncol."},{"key":"74124_CR35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41568-021-00397-3","volume":"21","author":"BM Andersen","year":"2021","unstructured":"Andersen, B. M. et al. Glial and myeloid heterogeneity in the brain tumour microenvironment. Nat. Rev. Cancer 21, 786\u2013802 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"74124_CR36","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.immuni.2023.07.015","volume":"56","author":"D Chen","year":"2023","unstructured":"Chen, D. et al. CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. Immunity 56, 2086\u20132104 (2023).","journal-title":"Immunity"},{"key":"74124_CR37","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1158\/1078-0432.CCR-19-3104","volume":"26","author":"JR Kane","year":"2020","unstructured":"Kane, J. R. et al. CD8(+) T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas. Clin. Cancer Res. 26, 4390\u20134401 (2020).","journal-title":"Clin. Cancer Res."},{"key":"74124_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606456","volume":"11","author":"C Mazewski","year":"2020","unstructured":"Mazewski, C., Perez, R. E., Fish, E. N. & Platanias, L. C. Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways. Front. Immunol. 11, 606456 (2020).","journal-title":"Front. Immunol."},{"key":"74124_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4048\/jbc.2021.24.e34","volume":"24","author":"S Banik","year":"2021","unstructured":"Banik, S., Rakshit, S. & Sarkar, K. The role of STAT1 in T helper cell differentiation during breast cancer progression. J. Breast Cancer 24, 253\u2013265 (2021).","journal-title":"J. Breast Cancer"},{"key":"74124_CR40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1471-4906(01)02005-1","volume":"22","author":"DM Frucht","year":"2001","unstructured":"Frucht, D. M. et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22, 556\u2013560 (2001).","journal-title":"Trends Immunol."},{"key":"74124_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"74124_CR42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity. Immunity 55, 308\u2013323 (2022).","journal-title":"Immunity"},{"key":"74124_CR43","doi-asserted-by":"publisher","unstructured":"Singh, K. et al. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2021-003679 (2021).","DOI":"10.1136\/jitc-2021-003679"},{"key":"74124_CR44","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","volume":"20","author":"SJ Bagley","year":"2018","unstructured":"Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H. & O\u2019Rourke, D. M. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 20, 1429\u20131438 (2018).","journal-title":"Neuro Oncol."},{"key":"74124_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","volume":"151","author":"R Medikonda","year":"2021","unstructured":"Medikonda, R., Dunn, G., Rahman, M., Fecci, P. & Lim, M. A review of glioblastoma immunotherapy. J. Neurooncol. 151, 41\u201353 (2021).","journal-title":"J. Neurooncol."},{"key":"74124_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41591-019-0355-0","volume":"25","author":"P Chongsathidkiet","year":"2019","unstructured":"Chongsathidkiet, P. et al. Author correction: sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 25, 529 (2019).","journal-title":"Nat. Med."},{"key":"74124_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."},{"key":"74124_CR48","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/eji.1830230617","volume":"23","author":"MW Schilham","year":"1993","unstructured":"Schilham, M. W. et al. Alloreactive cytotoxic T cells can develop and function in mice lacking both CD4 and CD8. Eur. J. Immunol. 23, 1299\u20131304 (1993).","journal-title":"Eur. J. Immunol."},{"key":"74124_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/ng.3711","volume":"49","author":"T Shingu","year":"2017","unstructured":"Shingu, T. et al. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat. Genet 49, 75\u201386 (2017).","journal-title":"Nat. Genet"},{"key":"74124_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"74124_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li, W. et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 16, 281 (2015).","journal-title":"Genome Biol."},{"key":"74124_CR52","unstructured":"Team, R. C. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2024)."},{"key":"74124_CR53","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"74124_CR54","unstructured":"Yu, G., Q.-Y.H., Wu, Y., & Ge, X. enrichplot: Visualization of Functional Enrichment Result (Bioconductor, 2024)."},{"key":"74124_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102383","volume":"4","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Isolation and profiling of viable tumor cells from human ex vivo glioblastoma cultures through single-cell transcriptomics. STAR Protoc. 4, 102383 (2023).","journal-title":"STAR Protoc."},{"key":"74124_CR56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s43018-024-00904-z","volume":"6","author":"M Ritter","year":"2025","unstructured":"Ritter, M. et al. Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics. Nat. Cancer 6, 292\u2013306 (2025).","journal-title":"Nat. Cancer"},{"key":"74124_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50904-x","volume":"15","author":"J Kueckelhaus","year":"2024","unstructured":"Kueckelhaus, J. et al. Inferring histology-associated gene expression gradients in spatial transcriptomic studies. Nat. Commun. 15, 7280 (2024).","journal-title":"Nat. Commun."},{"key":"74124_CR58","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40, 639\u2013655.e613 (2022).","journal-title":"Cancer Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74124-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74124-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74124-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:03:27Z","timestamp":1786100607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74124-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74124"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74124-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. Sonabend has received in-kind and or funding support for research from Agenus, BMS, and CarThera. A.M. Sonabend, V.A. Arrieta, and R. Rabadan are co-authors of IP filed by Northwestern University related to the content of this manuscript. A.M. Sonabend is a paid consultant for Carthera and Enclear Therapies. P.A. Sims. receives patent royalties from Guardant Health. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7968"}}